Hypertension is a heart-related disease which results in elevated blood pressure in the arteries. It is also known as arterial hypertension or high blood pressure. This disease occurs on account of alcohol, smoking, obesity, and other genetic factors. Although, the disease can be treated with a healthy diet and exercise, antihypertensives are recommended to control it.
Antihypertensives are a class of drugs which can prevent hypertension and other cardiovascular-related disorders like strokes and myocardial infarction. They are likely to reduce the heart conditions by 21%. Beta blockers, thiazide diuretics, ACE inhibitors, calcium channel blockers, and angiotensin II receptor antagonists (ARBs) are the different types of antihypertensive therapeutics in major developed markets.
Browse Detail Report With TOC @
http://hexareports.com/report/antihypertensive-therapeutics-in-major-developed-markets/details
Thiazide diuretics aid in reducing salt and water from the kidneys. They are the first drugs to be administered for a patient undergoing hypertension treatment. ACE inhibitors reduce serum creatinine levels better than beta blockers. They are considered the first line of defense against heart-related disorders. ARBs reduces the risko f myocardial infarction when combined with amlodipine. Beta blockers are considered risky and can lead to strokes or type-2 diabetes. However, they prevent heart attacks in persons who have already experienced a heart attack.
The hypertension market was estimated to have earned USD 40 billion of revenue in 2013. The market will attain USD 37 billion by 2020, owing to the patent expiry of major drugs. It is predicted to grow at a 2.6% CAGR during the period of 2014 to 2017. The market will experience growth on account of fixed-dose combination (FDCs) drugs, the rising geriatric population, and a low diagnosis rate.
FDCs include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna, Benicar HCT, Tekturna HCT, Tekamlo, and Edarbyclor. New drugs in the pipeline are AHU377 + valsartan and azilsartan + amlodipine. Patients undergoing the treatment were known to have reduced levels of blood pressure. Drugs about to lose their patent are Exforge in 2014, Cozaar in 2010, Tekturna and Tekturna HCT in 2018, Benicar in 2016, and Atacand and Avapro in 2012.
The hypertension market has evolved from creating drugs to providing step-by-step special treatment dependent on the seriousness of the disease. The new classes of antihypertensive drugs are able to protect the kidneys, liver, heart, and brain from internal damage.
Related Reports:
Global Plasma Coagulation Electrosurgical Unit Industry 2016 Market Research Report:
http://hexareports.com/report/global-plasma-coagulation-electrosurgical-unit-industry-2016
Global Medical Autoclave Industry 2016 Market Research Report:
http://hexareports.com/report/global-medical-autoclave-industry-2016
Europe Resectoscope Industry 2016 Market Research Report:
http://hexareports.com/report/europe-resectoscope-industry-2016
Table of Contents
Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Pathophysiology 8
2.2 Etiology 9
2.3 Signs and Symptoms 9
2.4 Co-Morbidities and Complications 10
2.5 Diagnosis 11
2.5.1 Office Blood Pressure Monitoring 11
2.5.2 Ambulatory Blood Pressure Monitoring 11
2.5.3 Home Blood Pressure Monitoring 11
2.5.4 Miscellaneous Methods 11
2.5.5 Diagnosis of Target Organ Damage 12
2.5.6 Diagnosis of Hypertension in Pregnancy 12
2.6 Classification 12
2.7 Epidemiology 13
2.8 Prognosis 14
2.9 Treatment and Management 14
2.9.1 Treatment Strategy 15
3 Marketed Products 19
3.1 Approved Products 19
3.1.1 Norvasc (amlodipine besylate) – Pfizer 19
3.1.2 Micardis (telmisartan) – Boehringer Ingelheim 21
3.1.3 Tekturna (aliskiren) – Novartis/Speedel 22
3.1.4 Benicar (olmesartan medoxomil) – Daiichi Sankyo 24
3.1.5 Diovan (valsartan) – Novartis 25
3.1.6 Cozaar (losartan) – Merck 27
3.1.7 Exforge (amlodipine + valsartan) – Novartis 29
3.2 Comparative Efficacy and Safety 31
4 Product Pipeline 33
4.1 Overall Pipeline 33
4.2 Pipeline Analysis by Molecules Type 34
4.3 Pipeline Analysis by Mechanism of Action Type 35
4.4 Clinical Trial Failure Rate 37
4.5 Patient Enrollment and Clinical Trial Size 39
4.6 Clinical Trial Duration 40
4.7 Promising Drug Candidates in Pipeline 41
4.7.1 LCZ696 (AHU-377 + valsartan) – Novartis 41
Request A Sample copy of This Report @ http://hexareports.com/sample/104209
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: sales@hexareports.com
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://hexareports.com/report/antihypertensive-therapeutics-in-major-developed-markets/details